Suzhou, China, April 7, 2021 - Suzhou Abogen Biosciences Co., Ltd. (“Abogen”) announces that it has raised RMB 600 million in Series B financing, led by PICC Capital Equity Investment Company Limited (PICC PE) and SDIC Venture Capital. New investors participating in this round also include YF Capital, Jifeng Venture, HighLight Capital(HLC), BioTrack Capital. Existing investors including GL Ventures, TF Capital, and Ming Bioventures continued to participate in this round of financing. The funds raised will be mainly used to advance Abogen's technology platform, speed up the construction of its R&D center and GMP facilities and further expand its product pipelines.
About Abogen
Abogen is a clinical-stage biotechnology company focused on advancing mRNA-based therapeutics for the treatment of cancer and other infectious diseases. Since its establishment in January 2019, Abogen has developed its own mRNA technology platform and proprietary delivery system which empowers the development of a series of drug product candidates including vaccines for infectious diseases and therapies for cancer.
